Tracer library / [90Y]Y-DOTA-Phe1-Tyr3-octreotide

[90Y]Y-DOTA-Phe1-Tyr3-octreotide

Also written as [Y-90]DOTA-Phe1-Tyr3-octreotide; Y-90-DOTA-Phe1-Tyr3-Octreotide

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Neuroendocrine neoplasms Peptide receptor radionuclide therapy

What it is

Compound class: Radiolabeled somatostatin analogue peptide
Target / mechanism: Somatostatin receptors (SSTR) PMID 19635228
Clinical application: Metastatic/progressive neuroendocrine (carcinoid) tumors PMID 19635228
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
2004 · Cancer Biother Radiopharm · Clinical study

Need this precursor?We can point you to suppliers for [90Y]Y-DOTA-Phe1-Tyr3-octreotide, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Stage was 'Phase I/II'; normalised to 'Clinical research', original wording kept here.